Avant’s Brain Cancer Vaccine Passes Phase II
This article was originally published in The Pink Sheet Daily
Recent deal with Pfizer could speed new trial, chief medical officer tells “The Pink Sheet” DAILY.
You may also be interested in...
Therapeutic vaccine is a “beautiful” match with temozolomide, Avant CEO tells “The Pink Sheet” DAILY.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.